ScripAlkermes’s initial release of Phase II trial results for alixorexton in narcolepsy type 1 (NT1) indicates that the company’s drug could prove highly competitive in the growing race among developers of
ScripTakeda is already in launch preparations for oveporexton as the drug produced positive results in two Phase III trials in narcolepsy type 1 (NT1), making approval likely while also clearing the way fo
ScripAdvice For Working With Trump The biotech industry is only about one month into working with a new administration in the US following the inauguration of Donald Trump as president – and the pace of
Pink SheetDespite the “chaotic” early days, experts said plenty of opportunities are available to work with President Donald Trump’s new administration, although the biopharma industry must frame lobbying effor